Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary pulmonary hypertension.

James R Runo1, James E Loyd

  • 1Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, T-1217 Medical Center North, Nashville, TN 37232-2650, USA.

Lancet (London, England)
|May 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insurance and Treatment Patterns in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Annals of the American Thoracic Society·2026
Same author

Newly diagnosed pulmonary arterial hypertension following liver transplantation: Insights from a multicenter case series.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

The Utility of Follow-up Transthoracic Echocardiogram to Screen for Severe Portopulmonary Hypertension (POPH) in Patients Granted POPH Model for End-stage Liver Disease (MELD) Exceptions.

Transplantation direct·2025
Same author

Complexities and outcomes of pulmonary hypertension in kidney transplant patients: a comprehensive review.

Turkish journal of nephrology·2024
Same author

The Genetic Landscape of Familial Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2023
Same author

Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.

Pulmonary circulation·2022

Primary pulmonary hypertension (PPH) involves high blood pressure in lung arteries. Genetic mutations and new therapies offer hope for understanding and treating this rare, progressive heart condition.

Area of Science:

  • Cardiology
  • Genetics
  • Pulmonary Medicine

Background:

  • Primary pulmonary hypertension (PPH) is a rare condition causing elevated pulmonary-artery pressure without secondary causes.
  • Pathological changes include medial hypertrophy, intimal fibrosis, and plexiform lesions in pre-capillary pulmonary arteries.
  • Patients often present with dyspnea or signs of right heart failure.

Purpose of the Study:

  • To review the current understanding of PPH, including its pathogenesis, diagnosis, and treatment.
  • To highlight the significance of bone morphogenetic protein receptor 2 gene mutations in PPH.
  • To discuss emerging therapeutic strategies for PPH.

Main Methods:

  • Literature review of PPH focusing on pathogenesis, diagnosis, and treatment.

Related Experiment Videos

  • Analysis of diagnostic tools, particularly echocardiography for screening.
  • Examination of genetic findings, including BMPR2 mutations.
  • Evaluation of current and novel therapeutic agents.

    • Main Results:

    • Echocardiography is the primary non-invasive screening tool for pulmonary hypertension.
    • Mutations in the bone morphogenetic protein receptor 2 gene are implicated in familial and sporadic PPH.
    • Current treatments like epoprostenol slow disease progression but do not halt it.
    • New therapies including prostacyclin analogues, endothelin-1-receptor antagonists, and phosphodiesterase inhibitors show promise.

    Conclusions:

    • PPH pathogenesis is complex and not fully understood, with ongoing research into modifier genes.
    • Genetic factors, such as BMPR2 mutations, play a crucial role in PPH development.
    • While current therapies offer some benefit, novel treatments are improving clinical outcomes and survival rates for PPH patients.